ANDA 65292, held by Hospira Inc. Cefotaxime Sodium.
As of Nov 16, 2026, ANDA 65292 (Cefotaxime Sodium), held by Hospira Inc, was first approved by FDA on Aug 10, 2006, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cefotaxime SodiumEQ 10GM BASE/VIAL ยท injectable;injection | Cefotaxime Sodium | Discontinued |
| Jun 26, 2012 | Supplement 2Labeling | Approved | None posted |
| Aug 10, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters